[Pubmed] Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab
Posté : 02 avr. 2022 12:00
Neurol Sci. 2022 Apr 2. doi: 10.1007/s10072-022-05922-2. Online ahead of print.
ABSTRACT
Eculizumab, a humanized monoclonal antibody, is a complement inhibitor indicated for refractory generalized myasthenia gravis (MG). However, there are limited data on the safety of eculizumab for MG during coronavirus disease 2019 (COVID-19) infection. We report a case in which eculizumab was continued for MG after contracting COVID-19, followed by a favorable outcome.
PMID:35364770 | DOI:10.1007/s10072-022-05922-2
Source: https://pubmed.ncbi.nlm.nih.gov/3536477 ... 7&v=2.17.6